Co-Diagnostics has entered an agreement with its joint venture partner CoSara Diagnostics to expand its commercial and distribution territory into Sri Lanka, Nepal, Pakistan, and Bangladesh.
The move significantly increases CoSara’s coverage in South Asia.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The expansion supports CoSara’s plans to commercialise the PCR Pro point-of-care instrument and Saragene product line throughout these regions, pending regulatory approvals in each country.
As part of this initiative, CoSara is currently assessing regulatory pathways, identifying target customer groups, and engaging with local distribution partners across the new markets.
CoSara CEO Mohal Sarabhai said: “South Asia represents a large and rapidly growing market for molecular diagnostics, with significant need for easily accessible, non-invasive, quick and reliable testing solutions.
“Expanding our territory allows us to begin building relationships with regional partners and positions us to support the future commercialisation of the point-of-care PCR platform across these markets, increasing access to molecular tests for tuberculosis, human papillomavirus, and upper respiratory infections.”
Co-Diagnostics CEO Dwight Egan said: “This expansion reflects our broader strategy of establishing regional infrastructure ahead of product commercialisation. By building local manufacturing and distribution capabilities in key regions, including the US, South Asia, and the Middle East and North Africa, we are positioning Co-Dx to support scalable, global deployment of our PCR point-of-care platform and drive long-term growth.”
To facilitate these efforts, CoSara will host a virtual distributor information session in Q2 2026.
Co-Diagnostics develops molecular diagnostic technologies used for detecting or analysing nucleic acid molecules.
The company also leverages proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platforms (pending regulatory review) and genetic marker identification for broader applications.
